Spots Global Cancer Trial Database for Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Official Title: Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins

Study ID: NCT01764451

Conditions

Cavernous Angioma, Familial

Cerebral Cavernous Malformations

Cerebral Cavernous Hemangioma

Interventions

Simvastatin

Study Description

Brief Summary: Cerebral cavernous malformations (CCMs) are clusters of abnormal blood vessels in the brain and spine. CCMs can bleed and cause strokes, seizures, and headaches. In some patients, CCMs affect the blood brain barrier (BBB). The BBB is the body's separation of blood and its contents in the brain from the brain tissue itself. Abnormal leakiness or permeability of this barrier can cause disease. We will measure the permeability (leakiness) of the BBB using a magnetic resonance imaging (MRI) technique called dynamic contrast-enhanced MRI (DCEMRI). The purpose of this study is to look at whether statin medications change the permeability (leakiness) of the blood brain barrier in CCM patients. Statin medications are used to lower cholesterol levels and prevent heart attack and stroke. In addition, this medication may decrease the risk of brain hemorrhage or bleeding in patients with CCM. This study will examine whether the permeability of the BBB changes following the administration of simvastatin for three months.

Detailed Description: